Peptide Tools to Study SARS-CoV-2

SARS-CoV-2 Spike Protein Arrested In the Closed State Induces Potent Neutralizing Responses
Carnell et al, bioRxiv (2021)
Robust SARS-CoV-2-specific T Cell Immunity is maintained at 6 Months Following Primary Infection
Zuo et al, Nature (2021)
SARS-CoV-2 Spike Protein Arrested in the Closed State Induces Potent Neutralizing Responses
Oh et al, bioRxiv (2021)
First Report Demonstrating the Safety and Immunogenicity of the SARS-COV-2 BNT162b1 mRNA Vaccine in Younger and Older Chinese Adults: A Randomized, Placebo-Controlled, Observer-Blind Phase I Study
Zhu et al, Research Square (2021)
1IL-2 and IFN-γ are Biomarkers of SARS-CoV-2 Specific Cellular  Response in Whole Blood Stimulation Assays
Pérez-Cabezas et al, medRxiv (2020)
Adaptive Immune Responses to SARS-CoV-2 in Recovered Severe COVID-19 Patients
Olea et al, medRxiv (2020)
Persistent Cellular Immunity to SARS-CoV-2 Infection
Breton et al, bioRxiv (2020)
Deconvoluting the T cell response to SARS-CoV-2: specificity versus chance- and cognate cross-reactivity
Lehmann et al, bioRxiv (2020)
Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development    
Holenya et a al, medRxiv (2020)
BNT162b2 Induces SARS-CoV-2-Neutralising Antibodies and T cells in Humans
Sahin et al, medRxiv (2020)
Convalescent Plasma Therapy for B-Cell Depleted Patients With Protracted COVID-19 Disease     
Hueso et al, Blood (2020)
Divergent SARS‐CoV‐2‐Specific T and B Cell Responses in Severe but Not Mild COVID‐19 Patients
Oja et al, European Journal of Immunology (2020)
mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents
Rauch et al, bioRxiv (2020)
T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
Candon et al, Am J Transplant  (2020)
Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
Gallais et al, Emerg Infect Dis (2020)
A Glimpse Into the Diverse Cellular Immunity Against SARS-CoV-2     
Chang  et al, Research Square (2020)
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and 2 non-human primates
Kalnin et al, bioRxiv (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in Older Adults
Anderson et al, NEJM (2020)
Divergent SARS-CoV-2-specific T and B cell Responses in Severe but Not Mild COVID-19
Oja et al, bioRxiv (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett et al, New England J of Med (2020)
Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
Braun et al, Nature (2020)
Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado et al, Nature (2020)
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Corbett et al, bioRxiv (2020)
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
Zecha et al, Mol Cell Proteomics (2020)
A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
Payen et al, medRXiv (2020)
SARS-CoV-2-specific T cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
Neidleman et al, bioRxiv (2020)
Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in vitro by Intracellular Aminopeptidases
Stamatakis et al bioRxiv (2020)
Self-amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
McKay et al, Nature 2020
An mRNA Vaccine Against SARS-CoV-2 — Preliminary Report
Jackson et al, New England J of Med (2020)
SARS‐CoV‐2‐Reactive Interferon‐γ‐producing CD8+ T cells in Patients Hospitalized with Coronavirus Disease 2019
Giminez et al, J Med Vir (2020)
Concurrent Human Antibody and TH1 type T-cell Responses 2 Elicited by a COVID-19 RNA Vaccine
Sahin et al, medRXiv (2020)

Further references